In Silico臨床試験の世界市場レポート 2024

In Silico臨床試験の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には8.7%の年間複合成長率（CAGR）で50億2,000万米ドルに成長すると予想されます。予測期間で予想される成長は、より迅速な医薬品開発プロセスに対する需要の高まり、臨床試験における仮想患者集団の採用、デジタルツイン技術の拡大、およびIn Silico試験の規制当局の受け入れの増加に起因すると考えられます。予測期間中に予想される主な動向には、より現実的な仮想患者モデルの開発、In Silico臨床試験における現実世界の証拠の統合、分散型で患者中心の試験設計の重視、デジタルバイオマーカーの使用の増加、および仮想臨床試験における個別化医療への注目が高まっています。

In Silico臨床試験市場は、慢性疾患、感染症、神経疾患の有病率の増加により成長が見込まれています。 1年以上続く慢性疾患は、継続的な医療の需要を生み出し、日常生活に影響を与えます。病原体によって引き起こされる感染症は、感染源との接触を通じて広がります。神経疾患は脊髄、神経、脳に影響を与えます。これらの疾患の増加により、薬剤や治療の改善が必要となり、医薬品開発を迅速化するためのIn Silico試験の利用につながります。たとえば、国立バイオテクノロジー情報センター（NCBI）は、2050年までに少なくとも1つの慢性疾患を患う50歳以上の人の数が99.5%増加すると予測しています。さらに、世界保健機関は、マラリア症例数が2020年の2億4,500万人から現在に至るまで増加していると報告しています。 2021年には2億4,700万人に達し、パーキンソン病財団は、新たにパーキンソン病と診断される人が2021年の60,000人から2022年 12月には90,000人に増加していると指摘しています。その結果、In Silico臨床試験の増加は、慢性疾患、感染症、神経疾患の有病率の拡大によって推進されています。

In Silico臨床試験市場の拡大は、臨床試験コストを削減する必要性によってさらに加速されています。臨床試験費用には、医療介入の安全性と有効性を評価するための試験の計画、実施、管理に関連する費用が含まれます。従来の治験は長期にわたり費用がかかり、10～15年かかり、数十億米ドルの費用がかかります。In Silico試験は、コンピューターシミュレーションを使用して介入を評価するという代替手段を提供します。たとえば、Genetic Engineering and Biotechnology Newsによると、世界のバイオ医薬品企業トップ 20社の新薬開発コストは、臨床試験開発費用を含め、2022年の2億9,800万米ドルから2023年には約23億米ドルに増加しました。 In Silico臨床試験へのこの移行は、これらの増大する出費を抑制する必要性の増大によって推進されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のIn Silico臨床試験市場、フェーズ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• フェーズI
• フェーズII
• フェーズⅢ
• フェーズIV
• 世界のIn Silico臨床試験市場、治療領域別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 腫瘍学
• 感染症
• 血液学
• 心臓病学
• 皮膚科
• 神経内科
• 糖尿病
• その他の治療領域
• 世界のIn Silico臨床試験市場、業界別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 医療機器
• 医薬品

第7章 地域および国の分析

• 世界のIn Silico臨床試験市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界のIn Silico臨床試験市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• In Silico臨床試験市場の競合情勢
• In Silico臨床試験市場の企業プロファイル
  • Dassault Systemes SE
  • Clarivate plc
  • Evotec AG
  • Evidera
  • Certara Inc.

第31章 その他の大手および革新的な企業

• Abzena Limited
• Selvita
• Simulations Plus Inc.
• Insilico Medicine Inc.
• AnyLogic Company
• Biomax Informatics
• GNS Healthcare Inc.
• 4P-Pharma
• Nuventra Pharma Sciences
• Archimedes
• Novadiscovery Sas
• Rosa &Co.
• In Silico Biosciences
• Leadscope
• Biognos Ab

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

In silico clinical trials, also known as virtual clinical trials, involve computer simulations used to develop or evaluate the safety and efficacy of medicinal products, devices, or interventions. They serve as a method to assess the safety and effectiveness of medical devices and imaging systems.

The primary phases of in silico clinical trials include Phase I, Phase II, Phase III, and Phase IV. Phase I represents the initial evaluation of a drug or treatment on a small group of people, aiming to assess the safety and tolerability of new drugs in humans. These trials are conducted across various medical domains such as oncology, infectious disease, hematology, cardiology, dermatology, neurology, diabetes, and others. In silico clinical trials find applications in both the medical devices and pharmaceutical industries.

The in silico clinical trials research report is one of a series of new reports from The Business Research Company that provides in silico clinical trials market statistics, including the in silico clinical trials industry's global market size, regional shares, competitors with in silico clinical trials market share, detailed in silico clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the in silico clinical trials industry. This in silico clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The in silico clinical trials market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.59 billion in 2024 at a compound annual growth rate (CAGR) of 8.6%. The growth observed in the historical period can be attributed to factors such as the increased availability of medical data, the evolution of regulatory frameworks for virtual trials, advancements in computing power, the rise in healthcare digitization, and the expansion of precision medicine initiatives.

The in silico clinical trials market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The anticipated growth in the forecast period can be attributed to the growing demand for faster drug development processes, the adoption of virtual patient populations in clinical trials, the expansion of digital twin technologies, and an increase in regulatory acceptance of in silico trials. Major trends expected in the forecast period include the development of more realistic virtual patient models, the integration of real-world evidence in in silico trials, an emphasis on decentralized and patient-centric trial designs, a rise in the use of digital biomarkers, and an increased focus on personalized medicine in virtual trials.

The in silico clinical trials market is anticipated to experience growth due to the increasing prevalence of chronic, infectious, and neurological diseases. Chronic diseases, lasting a year or more, create a demand for ongoing medical care and impact daily activities. Infectious diseases, caused by pathogens, spread through contact with infected sources. Neurological disorders affect the spinal cord, nerves, and brain. The rise in these diseases necessitates improved medications and treatments, leading to the utilization of in silico trials for expedited drug development. For example, the National Centre for Biotechnology Information (NCBI) projected a 99.5% surge in individuals aged 50 and older with at least one chronic illness by 2050. Additionally, the World Health Organization reported an increase in malaria cases from 245 million in 2020 to 247 million in 2021, and the Parkinson's Foundation noted a rise in new Parkinson's disease diagnoses from 60,000 in 2021 to 90,000 in December 2022. Consequently, the growth of in silico clinical trials is driven by the escalating prevalence of chronic, infectious, and neurological diseases.

The expansion of the in silico clinical trials market is further fueled by the need to reduce clinical trial costs. Clinical trial costs encompass the expenses associated with planning, conducting, and managing trials to assess the safety and efficacy of medical interventions. Traditional trials are lengthy and expensive, taking 10-15 years and costing billions. In silico trials offer an alternative, using computer simulations to evaluate interventions. For instance, according to Genetic Engineering and Biotechnology News, the cost of developing a new drug among the top 20 global biopharma companies rose from $298 million in 2022 to approximately $2.3 billion in 2023, including clinical trial development costs. This shift towards in silico clinical trials is driven by the growing need to curb these escalating expenses.

A prominent trend in the in silico clinical trials market is the emergence of strategic partnerships. Major companies in the market are forming partnerships to enhance their market position. For example, Premier Research, a US-based clinical research organization (CRO), partnered with InSilicoTrials to create efficient pathways for rare disease treatment approval. Similarly, 4P-Pharma, a France-based biotech company, collaborated with QuantHealth, an Israel-based AI company, to conduct patient-centric drug simulations, accelerating and de-risking drug development. These partnerships exemplify the industry trend of forming strategic alliances to strengthen market presence and facilitate advancements in in silico clinical trials.

Prominent players in the in silico clinical trials market are directing their focus towards cutting-edge technologies, specifically clinical trial platforms, to uphold their market positions. A clinical trial platform represents a specialized form of an adaptive, disease-centric, randomized clinical trial (RCT) formulated to assess multiple interventions concurrently against a consistent control group. As an illustration, in October 2023, Advarra, a US-based provider offering regulatory review solutions and clinical research technology for sites and sponsors, introduced Longboat v2.2. This new technological functionality aims to enhance the overall clinical trial experiences of stakeholders. Longboat, an established platform utilized in over 70 countries and by nearly 20,000 sites, now incorporates an online patient portal equipped with a comprehensive array of engagement tools. This includes a straightforward document exchange feature facilitating transparent collaboration among patients, sites, sponsors, or clinical research organizations (CROs), all while avoiding an additional technology burden.

In May 2023, Recursion, a US-based clinical-stage TechBio company, disclosed the acquisition of Cyclica and Valence for an undisclosed sum. These strategic acquisitions bring cutting-edge capabilities in digital chemistry, as well as machine learning and artificial intelligence from Cyclica and Valence. These capabilities are seamlessly integrated with Recursion's extensive automated wet-laboratories and supercomputing resources. This integration positions Recursion to deploy the most comprehensive, technology-enabled drug discovery solution within the biopharma industry. Cyclica, a biotechnology company based in Canada, and Valence, a Canadian deep learning research institute, collectively contribute to enhancing Recursion's capabilities in the pursuit of advancing drug discovery through innovative technologies.

Major companies operating in the in silico clinical trials market report are Dassault Systemes SE, Clarivate PLC, Evotec AG, Evidera, Certara Inc., Abzena Limited, Selvita, Simulations Plus Inc., Insilico Medicine Inc., AnyLogic Company, Biomax Informatics, GNS Healthcare Inc., 4P-Pharma, Nuventra Pharma Sciences, Archimedes, Novadiscovery Sas, Rosa & Co., In Silico Biosciences, Leadscope, Biognos Ab, BioNova, Immunetrics Inc., InSilicoTrials, Physiomics PLC, InhibOx, Entelos

North America was the largest region in the in silico clinical trials market in 2023. Asia-Pacific is expected to be the fastest-growing region in the in silico clinical trials market report during the forecast period. The regions covered in the in silico clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the in silico clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The in silico clinical trials market includes revenues earned by entities by providing services such as data management, trial design, information compilation and site support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

In Silico Clinical Trials Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on in silico clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for in silico clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The in silico clinical trials market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Phase: Phase I; Phase II; Phase III; Phase IV
• 2) By Therapeutic Area: Oncology; Infectious Disease; Hematology; Cardiology; Dermatology; Neurology; Diabetes; Other Therapeutic Areas
• 3) By Industry: Medical Devices; Pharmaceutical
• Companies Mentioned: Dassault Systemes SE; Clarivate plc; Evotec AG; Evidera; Certara Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. In Silico Clinical Trials Market Characteristics

3. In Silico Clinical Trials Market Trends And Strategies

4. In Silico Clinical Trials Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global In Silico Clinical Trials Market Size and Growth

• 5.1. Global In Silico Clinical Trials Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global In Silico Clinical Trials Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global In Silico Clinical Trials Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. In Silico Clinical Trials Market Segmentation

• 6.1. Global In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Phase I
• Phase II
• Phase III
• Phase IV
• 6.2. Global In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oncology
• Infectious Disease
• Hematology
• Cardiology
• Dermatology
• Neurology
• Diabetes
• Other Therapeutic Areas
• 6.3. Global In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medical Devices
• Pharmaceutical

7. In Silico Clinical Trials Market Regional And Country Analysis

• 7.1. Global In Silico Clinical Trials Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global In Silico Clinical Trials Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific In Silico Clinical Trials Market

• 8.1. Asia-Pacific In Silico Clinical Trials Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China In Silico Clinical Trials Market

• 9.1. China In Silico Clinical Trials Market Overview
• 9.2. China In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India In Silico Clinical Trials Market

• 10.1. India In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan In Silico Clinical Trials Market

• 11.1. Japan In Silico Clinical Trials Market Overview
• 11.2. Japan In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia In Silico Clinical Trials Market

• 12.1. Australia In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia In Silico Clinical Trials Market

• 13.1. Indonesia In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea In Silico Clinical Trials Market

• 14.1. South Korea In Silico Clinical Trials Market Overview
• 14.2. South Korea In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe In Silico Clinical Trials Market

• 15.1. Western Europe In Silico Clinical Trials Market Overview
• 15.2. Western Europe In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK In Silico Clinical Trials Market

• 16.1. UK In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany In Silico Clinical Trials Market

• 17.1. Germany In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France In Silico Clinical Trials Market

• 18.1. France In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy In Silico Clinical Trials Market

• 19.1. Italy In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain In Silico Clinical Trials Market

• 20.1. Spain In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe In Silico Clinical Trials Market

• 21.1. Eastern Europe In Silico Clinical Trials Market Overview
• 21.2. Eastern Europe In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia In Silico Clinical Trials Market

• 22.1. Russia In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America In Silico Clinical Trials Market

• 23.1. North America In Silico Clinical Trials Market Overview
• 23.2. North America In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA In Silico Clinical Trials Market

• 24.1. USA In Silico Clinical Trials Market Overview
• 24.2. USA In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada In Silico Clinical Trials Market

• 25.1. Canada In Silico Clinical Trials Market Overview
• 25.2. Canada In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America In Silico Clinical Trials Market

• 26.1. South America In Silico Clinical Trials Market Overview
• 26.2. South America In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil In Silico Clinical Trials Market

• 27.1. Brazil In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East In Silico Clinical Trials Market

• 28.1. Middle East In Silico Clinical Trials Market Overview
• 28.2. Middle East In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa In Silico Clinical Trials Market

• 29.1. Africa In Silico Clinical Trials Market Overview
• 29.2. Africa In Silico Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa In Silico Clinical Trials Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa In Silico Clinical Trials Market, Segmentation By Industry, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. In Silico Clinical Trials Market Competitive Landscape And Company Profiles

• 30.1. In Silico Clinical Trials Market Competitive Landscape
• 30.2. In Silico Clinical Trials Market Company Profiles
  • 30.2.1. Dassault Systemes SE
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Clarivate plc
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Evotec AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Evidera
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Certara Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. In Silico Clinical Trials Market Other Major And Innovative Companies

• 31.1. Abzena Limited
• 31.2. Selvita
• 31.3. Simulations Plus Inc.
• 31.4. Insilico Medicine Inc.
• 31.5. AnyLogic Company
• 31.6. Biomax Informatics
• 31.7. GNS Healthcare Inc.
• 31.8. 4P-Pharma
• 31.9. Nuventra Pharma Sciences
• 31.10. Archimedes
• 31.11. Novadiscovery Sas
• 31.12. Rosa & Co.
• 31.13. In Silico Biosciences
• 31.14. Leadscope
• 31.15. Biognos Ab

32. Global In Silico Clinical Trials Market Competitive Benchmarking

33. Global In Silico Clinical Trials Market Competitive Dashboard

34. Key Mergers And Acquisitions In The In Silico Clinical Trials Market

35. In Silico Clinical Trials Market Future Outlook and Potential Analysis

• 35.1 In Silico Clinical Trials Market In 2028 - Countries Offering Most New Opportunities
• 35.2 In Silico Clinical Trials Market In 2028 - Segments Offering Most New Opportunities
• 35.3 In Silico Clinical Trials Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer